COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced thro…
An institutional-grade, numbers-driven thesis on CMPS — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 16, 2026, TradersQuant's model rates COMPASS Pathways plc (CMPS) 55/100 with a 12-month base-case forecast of $19.10 — +42.0% versus the current price of $13.45. COMPASS Pathways plc trades at $13.45 in the Healthcare sector, with a market capitalisation of $1.81B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for CMPS is $19.10, implying +42.0% versus the current price. The model's 12-month scenario range runs from $17.32 (bear) to $29.15 (bull), with a base case of $22.27.
On the fundamentals, COMPASS Pathways shows a P/E of -2.9, trailing revenue of $0, revenue growth of +0.0% YoY. This page also tracks CMPS's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
CMPS currently carries a TradersQuant composite score of 55/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $19.10 implies +42.0% from $13.45. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for CMPS is $19.10, about +42.0% versus the latest price of $13.45. Consensus is based on 15 analysts.
TradersQuant's 12-month model forecast for CMPS is a base case of $22.27, ranging from $17.32 (bear) to $29.15 (bull), an expected return of +65.6%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for CMPS over the next 12 months is $22.27 in the base case (bear $17.32, bull $29.15), versus today's price of $13.45. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for CMPS — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates CMPS's fair value at $19.10, implying +42.0% of expected upside versus the current price.
COMPASS Pathways does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
